Korean Pro-Innovation Pricing Steps Draw Mixed Responses
Executive Summary
Amid pharma industry’s repeated calls to improve the drug pricing system and properly reflect R&D cost of novel drugs, South Korea released steps that include hiking prices of “global innovative novel drugs” and biomedicines. Response is mixed, with foreign pharmas complaining the steps focus mainly on domestically developed drugs.